At the American Society of Hematology meeting in December, the company reported that a Phase II study demonstrated higher rates of objective response and an improvement in event-free survival in AML patients who received volasertib in combination with chemotherapy compared to chemotherapy alone
Mundipharma International Corp., of Cambridge, UK, said results from the StiL NHL-1 study published in The Lancet showed that a first-line treatment regimen of bendamustine plus Rituxan (rituximab, Biogen Idec Inc. and Roche AG) doubled progression-free survival compared with CHOP plus rituximab in newly diagnosed patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma (69.5 months vs. 31.2 months; p < 0.0001
Primary endpoints will estimate the maximum tolerated dose and safety, while secondary endpoints include pharmacokinetics, progression-free survival and overall survival
The two-part study will feature a dose-escalation portion testing the drugs in combination as a second-line treatment, while the second part will be an open-label, randomized study to determine whether treatment with dalantercept plus axitinib can prolong progression-free survival (PFS) vs...The open-label, single-arm study will enroll about 37 patients after failure of second-line therapy, with a primary endpoint of overall response rate and secondary endpoints including progression-free survival
The study will compare CRXL101 to topotecan as second-line therapy, with co-primary endpoints of progression-free survival (PFS) and three-month PFS rate...The primary objectives of the trial are objective response rate and progression-free survival
The primary endpoint is progression-free survival per independent review facility assessment using the revised response criteria for malignant lymphoma
Secondary endpoints will include proportion of patients achieving therapy cessation three years after stable MMR, cost of therapy, overall survival, progression-free survival and treatment failure rates at five years
Onyx Pharmaceuticals Inc., of South San Francisco, and Bayer AG, of Leverkusen, Germany, reported that a Phase III trial of Nexavar (sorafenib) in locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer met its primary endpoint of a statistically significant improvement of progression-free survival
The primary endpoint is disease control rate at 16 weeks, while secondary endpoints will include the incidence and severity of adverse events, global DNA methylation levels, methylation status of selected tumor suppressor genes in tumor tissue, progression-free survival and overall survival
The primary objective is progression-free survival at 60 days, while secondary objectives include comparing the treatment arms for PSA responses, objective responses, time to progression, circulating tumor cells and other biomarkers
free survival rate of 63 percent after a median follow-up of 22.7 months...The primary endpoint of the study is immune-related progression-free survival at six months
The second Phase III trial resulted in a median two-year progression-free survival rate of 92 percent in patients with diffuse large B-cell lymphoma who received maintenance lenalidomide, compared with 83 percent for patients receiving lenalidomide plus Rituxan (rituximab, Biogen Idec Inc. and Roche AG...Pharmacyclics Inc., of Sunnyvale, Calif., presented various results for ibrutinib (PCI-32765) showing prolonged progression-free survival with a favorable safety profile in a number of indications
The study is testing tasquinimod in patients with metastatic castrate-resistant prostate cancer, with radiological progression-free survival as the primary endpoint and overall survival as a secondary endpoint
Pfizer Inc., of New York, said randomized Phase II data showed that PD-0332991 in combination with letrozole significantly extended progression-free survival (PFS) compared to letrozole alone in postmenopausal women with estrogen receptor-positive human epidermal growth factor receptor-1-negative locally advanced or metastatic breast cancer
At the American Society of Hematology meeting in December, the company reported that a Phase II study demonstrated higher rates of objective response and an improvement in event-free survival in AML patients who received volasertib in combination with chemotherapy compared to chemotherapy alone